Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The goals of this retrospective study were to determine the patient characteristics of dogs with high-grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow-up information available. The most common clinical signs included lethargy, anorexia and polyuria/polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T-cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization (WHO) lymphoma classification scheme. The overall progression-free survival (PFS) and overall survival (OS) were 133 and 183days, respectively. Treatment with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) protocol was associated with an improved PFS (144days) and OS (194days) when compared with dogs that received other medical therapies (P=.005 and P=.002, respectively); the absence of pleural effusion at diagnosis was associated with an increased OS but not PFS. These results suggest that while the prognosis for dogs with mediastinal lymphoma is poor, survival may be improved with treatment using a CHOP-based protocol.

Original languageEnglish (US)
JournalVeterinary and Comparative Oncology
DOIs
StateAccepted/In press - 2017

Fingerprint

lymphoma
Lymphoma
Dogs
Disease-Free Survival
Survival
dogs
Pleural Effusion
Polydipsia
vincristine
prednisone
Polyuria
hypercalcemia
Lethargy
doxorubicin
cyclophosphamide
Hypercalcemia
World Health Organization
Anorexia
Vincristine
Therapeutics

Keywords

  • CHOP
  • Canine
  • Chemotherapy
  • Mediastinum
  • T-cell lymphoma

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{0581f4fdde294097a0dece9c3eb209c8,
title = "Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma",
abstract = "The goals of this retrospective study were to determine the patient characteristics of dogs with high-grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow-up information available. The most common clinical signs included lethargy, anorexia and polyuria/polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T-cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization (WHO) lymphoma classification scheme. The overall progression-free survival (PFS) and overall survival (OS) were 133 and 183days, respectively. Treatment with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) protocol was associated with an improved PFS (144days) and OS (194days) when compared with dogs that received other medical therapies (P=.005 and P=.002, respectively); the absence of pleural effusion at diagnosis was associated with an increased OS but not PFS. These results suggest that while the prognosis for dogs with mediastinal lymphoma is poor, survival may be improved with treatment using a CHOP-based protocol.",
keywords = "CHOP, Canine, Chemotherapy, Mediastinum, T-cell lymphoma",
author = "Moore, {E. L.} and William Vernau and Rebhun, {Robert B} and Skorupski, {Katherine A} and Burton, {Jenna H}",
year = "2017",
doi = "10.1111/vco.12331",
language = "English (US)",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma

AU - Moore, E. L.

AU - Vernau, William

AU - Rebhun, Robert B

AU - Skorupski, Katherine A

AU - Burton, Jenna H

PY - 2017

Y1 - 2017

N2 - The goals of this retrospective study were to determine the patient characteristics of dogs with high-grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow-up information available. The most common clinical signs included lethargy, anorexia and polyuria/polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T-cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization (WHO) lymphoma classification scheme. The overall progression-free survival (PFS) and overall survival (OS) were 133 and 183days, respectively. Treatment with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) protocol was associated with an improved PFS (144days) and OS (194days) when compared with dogs that received other medical therapies (P=.005 and P=.002, respectively); the absence of pleural effusion at diagnosis was associated with an increased OS but not PFS. These results suggest that while the prognosis for dogs with mediastinal lymphoma is poor, survival may be improved with treatment using a CHOP-based protocol.

AB - The goals of this retrospective study were to determine the patient characteristics of dogs with high-grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow-up information available. The most common clinical signs included lethargy, anorexia and polyuria/polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T-cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization (WHO) lymphoma classification scheme. The overall progression-free survival (PFS) and overall survival (OS) were 133 and 183days, respectively. Treatment with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) protocol was associated with an improved PFS (144days) and OS (194days) when compared with dogs that received other medical therapies (P=.005 and P=.002, respectively); the absence of pleural effusion at diagnosis was associated with an increased OS but not PFS. These results suggest that while the prognosis for dogs with mediastinal lymphoma is poor, survival may be improved with treatment using a CHOP-based protocol.

KW - CHOP

KW - Canine

KW - Chemotherapy

KW - Mediastinum

KW - T-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85021457637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021457637&partnerID=8YFLogxK

U2 - 10.1111/vco.12331

DO - 10.1111/vco.12331

M3 - Article

C2 - 28660709

AN - SCOPUS:85021457637

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

ER -